·ï»ËÍøØ¹ú²úÐÂÒ»´úALKÒÖÔì¼Á¡ª¡ªBodog¹ÙÍøÔìÒ©ÒÁ³°¢¿ËÁÙ´²Êý¾Ý¹ú¼Ê³õ´Î°ä²¼
ABOUT US
·ï»ËÍøØ¹ú²úÐÂÒ»´úALKÒÖÔì¼Á¡ª¡ªBodog¹ÙÍøÔìÒ©ÒÁ³°¢¿ËÁÙ´²Êý¾Ý¹ú¼Ê³õ´Î°ä²¼
°ä²¼¹¦·ò£º
2022-02-26
½üÈÕ£¬ÓɳÛÃû·Î°©×¨¼Ò¡¢Öйúҽѧ¿ÆÑ§ÔºÖ×ÁöҽԺʯԶ¿½ÌÊÚÖ÷µ¼µÄ¹ú²ú´´ÐÂÒ©ÎïÒÁ³°¢¿ËIÆÚÁÙ´²×êÑÐÁ˾ÖSafety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial ÕýʽÔÚÆÚ¿¯Signal Transduction and Targeted Therapy£¨¡¶ÐźÅתµ¼ºÍ°ÐÏòÒ½ÖΡ·£©È«Îİ䷢¡£
ÒÁ³°¢¿ËƬÊÇÓÉBodog¹ÙÍøÔìÒ©×ÔÖ÷Ñз¢µÄÐÂÐÍALK/ROS1ÒÖÔì¼Á£¬¿ÉÒÖÔì·ÖÆçÈÚºÏÀàÐ͵ÄÒ°ÉúÐÍÒÔ¼°ALKÒÖÔì¼ÁÄÍÒ©Í»±äµÄALK¼¤Ã¸»îÐÔ£¬Í¬Ê±¿ÉÓÐЧÒÖÔì·ÖÆçÈÚºÏÀàÐÍROS1¼¤Ã¸µÄ»îÐÔ¡£

ÎÄÕÂϵͳ½éÉÜÁËÒÁ³°¢¿ËÔÚ¢ñÆÚ¼ÁÁ¿µÝÔö¼°ÈËȺÀ©´ó½×¶ÎÖа²È«ÐÔ¡¢ÄÍÊÜÐÔ¼°³õ²½ÁÆÐ§µÈµÄÈ«Ãæ·ÖÎö¡£¼ÁÁ¿µÝÔö½×¶ÎµÄÖØÒªÖÕµãÖ¸±êΪ×î´óÄÍÊܼÁÁ¿£¨MTD£©£¬¼ÁÁ¿ÏÞ¶ÈÐÔ¶¾ÐÔ£¨DLT£©ºÍ°²È«ÐÔ£¬ÈËȺÀ©´ó½×¶ÎµÄÖØÒªÖÕµãÖ¸±êΪ×êÑÐÕ߯À¹ÀµÄ¿Í¹Û»º½âÂÊ£¨ORR£©¡£×Ô2017Äê9ÔÂ25ÈÕÖÁ2018Äê10ÔÂ15ÈÕ£¬µÝÔö½×¶Î¹²Èë×é54ÀýALK/ROS1+ NSCLC»¼Õߣ¬À©´ó½×¶Î¹²Èë×é99ÀýALK/ROS1+ NSCLC»¼Õߣ¬¹²¼Æ153Àý»¼Õß½ÓÊÜÁËÒÁ³°¢¿ËƬҽÖΣ¬±¾×êÑÐδ»ñµÃMTD¡£µÝÔö½×¶ÎºÍÀ©´ó½×¶ÎµÄÕûÌåORR±ðÀëΪ59.3% (32/54)ºÍ56.6% (56/99)¡£ÆäÖУ¬Î´½ÓÊܹýALKÒÖÔì¼ÁÒ½ÖεÄALK+NSCLC»¼ÕßÖУ¬Á½½×¶ÎµÄORR±ðÀëΪ81.0% (17/21) ºÍ76.3% (29/38)£»¼ÈÍù½ÓÊܹý¿ËßòÌæÄáÒ½ÖεÄALK+NSCLC»¼ÕßÖУ¬Á½½×¶ÎµÄORR±ðÀëΪ38.1% (8/21) ºÍ 45.7% (21/46)¡£ÔÚROS1+NSCLC»¼ÕßÖУ¬µÝÔöºÍÀ©´ó½×¶ÎµÄORR±ðÀëΪ30.0% (3/10)ºÍ44.4% (4/9)¡£ÒÔÉÏÊý¾ÝÏÔʾ£¬ÒÁ³°¢¿ËÔÚALK/ROS1+ NSCLC»¼ÕßÖÐÓµÓÐÓÅÁ¼µÄ°²È«ÐÔ¡¢ÄÍÊÜÐԺͿ¹Ö×Áö»îÐÔ¡££¨µÝÔöºÍÀ©´ó½×¶ÎÖл¼ÕßÖ×ÁöÏà¶Ô»ùÏ߱䶯µÄ×î´ó°Ù·Ö±È¼ûͼaºÍͼb£©
·Î°©ÊÇĿǰȫÇò×î³£¼ûµÄ¶ñÐÔÖ×Áö£¬Ò²ÊǶñÐÔÖ×ÁöéæÃüµÄÊ×λÔÒò£¬Ô¼Õ¼ËùÓжñÐÔÖ×ÁöéæÃüµÄ18%¡£ÎÒ¹ú·Î°©µÄ·¢²¡Âʼ°éæÃüÂÊÔö³¤Ñ¸ËÙ£¬ÒѳÉΪÎÒ¹ú¶ñÐÔÖ×Áö·¢²¡ºÍéæÃüµÄÊ×λÔÒò¡£·ÇÓ×ϸ°û·Î°©£¨NSCLC£©ÊǷΰ©ÖÐ×î³£¼ûµÄ²¡Àí×é֯ѧÀàÐÍ£¬Ô¼Õ¼·Î°©µÄ85£¥£¬ÆäÔçÆÚÕï¶ÏÄÑ»¼ÕßÔ¤ºó²î£¬ÍùÍùÒѾȷÕï¾ÍÒѾ´¦ÓÚÍíÆÚ£¬ÊǷΰ©»¼ÕßÖÂËÀÂʸߵÄÖØÒªÔÒò¡£
½üÄêÀ´£¬ÍíÆÚ·ÇÓ×ϸ°û·Î°©ÔÚÒ½Öη½Ãæ³öÏÖ³Á´óµÄģʽת±ä¡£¹Ø¼üÖ°©ÐÔÍ»±ä£¨ÈçÇý¶¯»ùÒòÍ»±äºÍȾɫÌå³ÁÅÅ£©µÄ·¢ÏÖ£¬Ê¹µÃ°ÐÏòÒ½ÖÎÏà±È´«Í³µÄϸ°û¶¾ÐÔ»¯Ñ§ÁÆ·¨ÏÔʾ³ö¸ü¸ßµÄÃô¸ÐÐÔ¡£¼ä±äÐÔÁܰÍÁö¼¤Ã¸£¨ALK£©»ùÒòÍ»±äÓÉÓÚ²úÉúÂʵͣ¬µ«¶Ô°ÐÏòÒ½ÖÎÃô¸ÐÐԺã¬Éú¼Æ¹¦·ò³¤±»³ÆÎª·Î°©µÄ“×êʯͻ±ä”¡£¿ËßòÌæÄáÊǵÚÒ»´úÕë¶ÔALK+NSCLCµÄ°ÐÏòÒ©ÎALK-TKI£©£¬Ö»¹Ü»¼Õß¶Ô¿ËßòÌæÄáµÄÒ½ÖÎÓÐÓÅÁ¼µÄ·´Ó³£¬µ«´óÎÞÊý»¼Õß×îÖÕ»á²úÉúÄÍÒ©£¬Ô̺¬Ô·¢ÄÍÒ©ºÍ¼Ì·¢ÄÍÒ©£¬²¢ÇÒ¿ËßòÌæÄá¶Ô¹é²¢ÄÔ×ªÒÆÕßµÄÁÆÐ§²»¾¡ÈçÈËÒâ¡£°¢À´ÌæÄá×÷ΪµÚ¶þ´úALK-TKIµÄ´ú±í¹ÌÈ»±»Ö¤Ã÷ÓµÓи߶ÈÑ¡ÔñÐÔºÍÂÄÚ²¡Ôî½ÚÔìÂÊ£¬µ«ÏÕЩËùÓеϼÕßÒ²»áÔٴνøÕ¹ÎªTKIÄÍÒ©£¬Òò¶øALK+NSCLC»¼ÕßÒÀÈ»´æÔڽϴóδ±»Âú×ãµÄÒ½ÖÎÐèÒª¡£
ÕýÊÇÔÚÕâÒ»²¼¾°Ï£¬Bodog¹ÙÍøÔìÒ©»ý¼«²¼¾Ö£¬Ö´ÐÐÁËÒ»Àà´´ÐÂÒ©ÎïÒÁ³°¢¿ËÑз¢ÏîÄ¿¡£ÓÚ2016Äê5Ô³õ´ÎÉ걨ÁÙ´²£¬2017Äê10Ô³õ´Î¹«Ê¾Æô¶¯ÁÙ´²£¬NDAÒÑÓÚ2021Äê7ÔÂÌá½»ÖÁCDE²¢»ñµÃÊÜÀí¡£
¾ÝϤ£¬Bodog¹ÙÍøÔìÒ©±¾´ÎÉêÇëÉÏÊеÄÊÊӦ֢Ϊ“ºÏÓÃÓÚ¼ÈÍù½ÓÊܹý¿ËßòÌæÄáÒ½Öκ󼲲¡½øÕ¹»ò¶Ô¿ËßòÌæÄá²»ÄÍÊܵļä±äÐÔÁܰÍÁö¼¤Ã¸£¨ALK£©ÑôÐԵIJ¿ÃÅÍíÆÚ»ò×ªÒÆÐÔ·ÇÓ×ϸ°û·Î°©£¨NSCLC£©»¼ÕßµÄÒ½ÖΔ£¬Êý¾ÝÆðÔ´ÓÚÒ»Ïîµ¥±Û¡¢¢òÆÚÁÙ´²×êÑС£
²úÆ·ÓÐÍûÓÚ½ñÄêϰëÄêÔÚ¹úÄÚÉÏÊУ¬ÎªÖйúÍíÆÚALKÑôÐÔ·ÇÓ×ϸ°û·Î°©»¼ÕßÌṩеÄÒ½ÖÎÑ¡Ôñ¡£
ÓйØÐÂÎÅ
лªÍøØBodog¹ÙÍøÔìÒ©°¬ÅÁÂåÀûÍÐÎÖÈðÀûµ¥¿¹×¢ÉäÒºÐÂÊÊÓ¦Ö¢ÉÏÊÐÉêÇë»ñCDEÊÜÀí
2026-05-04
µç»°£º0531-83126666 / 7777 / 8888 / 9999
Ò©Îï½è¼ø¿Í·þÈÈÏߣº400-127-7799
´«Õ棺0531-83126688 / 9688
µØÖ·£ºÉ½¶«Ê¡³à·åÊиßÐÂÇøÓÎÀÀ·8888ºÅ
ÓÊÏ䣺wangzhan@qilu-pharma.com
¹©¸øÉÌÖÎÀíÈËÔ±
³ö²úÀ๩¸øÉÌÖÎÀí
Àî¡¡»¢ 0531-83126624
ÕÅê»î£ 0531-55820677
ÐÏ¡¡Ó¯ 0531-55820612
¾®Î¬ÖÞ 0531-55820837
·Ç³ö²úÀ๩¸øÉÌÖÎÀí
Õźé·å 0531-83129021
Ì·ºìÑÒ 0531-83129023
Ñз¢À๩¸øÉÌÖÎÀí
Àî½ð»¨ 0531-55820602
ÀîÕñ½ 0531-55820848
·þÎñÀ๩¸øÉÌÖÎÀí
·½¡¡Á¢ 0531-55820861
ÕÔ²ý¹ó 0531-55820857
¼à¶½¾Ù±¨
Ðİ®µÄºÏ×÷ͬ°é£º
»¶Ó¾Ù±¨ÒÔÏÂÐÐΪ£¡
Ë÷»ß¡¢°µÏä°Ñ³ÖÕбꡢÄÚ¶¨Öб굥Ԫ¡¢Ô±¹¤»òÇ×Êô²Î¼Ó¹«Ë¾ÒµÎñÍùÀ´Ä²È¡Ë½Àû¡¢Íµ¹¤¼õÁÏ¡¢ÒԴγäºÃ¡¢ÓÐÒâµóÄѹ©¸øÉ̵ÈÐÐΪ¡£
¾Ù±¨µç»°£º0531-83126898/55820713/83126871
¾Ù±¨ÓÊÏ䣺qljc@qilu-pharma.com
ÊÕÐŵØÖ·£ºÉ½¶«Ê¡³à·åÊÐÀú³ÇÇøÓÎÀÀ·8888ºÅ
Bodog¹ÙÍøÔìÒ©¼¯ÍÅÉ󼯼à²ì²¿
²É¹ºÆ½Ì¨¼¼ÊõרÏß

0531-83126666
wangzhan@qilu-pharma.com